CD3xMOSPD2 BiTE

N/A

Report date: 2026/03/19 16:59:32

Base Information

Drug NameCD3xMOSPD2 BiTE

Drug Alias Nameanti-CD3/anti-MOSPD2 bispecific T-cell engager (VBL Therapeutics)VB-600

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsMotile sperm domain-containing protein 2 modulators

TargetsMotile sperm domain-containing protein 2T cell surface glycoprotein CD3

Therapy Area/IndicationsUterine Cervical NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIreland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNotable Labs Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNotable Labs Ltd

Inactive CompaniesN/A

Active IndicationsUterine Cervical NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A